Core Insights - The article emphasizes that chronic disease management in China is entering a new era driven by AI, highlighting the importance of technology in addressing healthcare challenges posed by an aging population [1][2] - The online chronic disease management market in China is projected to grow significantly, with a compound annual growth rate of 44.5%, from 45.5 billion yuan in 2023 to 600 billion yuan by 2030 [1] - Ark Health's AI-driven approach aims to create a patient-centered healthcare model, leveraging technology to enhance doctor-patient relationships and improve service efficiency [2][3] Technology Development - Ark Health's "Xing Shi Medical Model" is designed to integrate various intelligent components into a collaborative service team, aiming for state-of-the-art performance [3] - The AI assistant has reportedly saved doctors over 60,000 hours of time through its diagnostic and case analysis capabilities [3] - The company has developed five core AI products, including AI Medication Finder and AI Health Manager, which aim to enhance clinical decision-making and knowledge dissemination [4] Strategic Collaborations - Ark Health has formed strategic partnerships with pharmaceutical companies, such as Innovent Biologics, to target the rapidly growing weight management market, which is expected to reach 149 billion yuan by 2030 [6][7] - The collaboration with Innovent focuses on integrating AI technology with innovative weight loss products, providing comprehensive support for patients [6][8] - The partnership with Zhejiang Otsuka Pharmaceutical aims to enhance drug service offerings and health education through AI capabilities [7][8]

Core Viewpoint - The article highlights the positive market response to the announcement by Gilead Sciences-B (01672) regarding its long-acting subcutaneous formulation ASC30 for weight management, which shows a promising 75-day apparent half-life in obese subjects, indicating potential for quarterly dosing in the future [1] Company Developments - Gilead Sciences' stock rose over 4%, reaching HKD 11.63 with a trading volume of HKD 37.09 million following the announcement [1] - The ASC30 formulation is developed using Gilead's Ultra Long-Acting Pharmaceutical (ULAP) platform, showcasing the company's innovation in drug development for obesity management [1] Clinical Trials and Future Prospects - Gilead's major shareholder has committed to a voluntary lock-up, agreeing not to sell any shares before the release of three key clinical data points: 1. Topline data from the U.S. Phase I clinical study of ASC47 combined with semaglutide, expected by the end of September 2025 2. Topline data from the U.S. 13-week Phase IIa clinical study of ASC30 oral tablets in overweight or obese subjects, expected by December 2025 3. Topline data from the U.S. Phase I single ascending dose study of ASC50 in healthy subjects, expected by December 2025 [1]

智通财经APP获悉，粉笔(02469)涨超5%，截至发稿，涨5.15%，报3.06港元，成交额1.96亿港元。 消息面上，今年4月，粉笔上线AI刷题系统班，定价399元，AI产品可以实时规划学习数据、动态定制 并调整学习计划，极大提升用户体验。截至2025年6月30日，已销售5万份，累计销售额约2000万元。此 外，8月底，粉笔AI矩阵再次迎来创新升级——事业单位AI刷题班正式上线，公司计划于年内在更多科 目推出AI大班课。值得一提的是，粉笔智能音箱上月正式上线并开启预售，24小时内，1400台预售库 存全部售罄。 国海证券指出，粉笔是公考培训赛道头部企业，产品、研发、技术能力优秀，看好AI产品渗透率提 升，带来增量收入空间。华泰证券则预计下半年随着国考临近，AI刷题班有望加速放量，预计全年销 量有望接近20万人次。考虑到新的AI产品具备更低的定价、更个性化和高效的学习体验、更难被盗版 等特征，在当下市场环境下具备较强竞争力和更稳健的盈利能力，该行认为中长期AI产品有望逐步替 代传统产品形态，并向更广泛的长尾用户渗透，推升用户增长和盈利天花板。 ...

智通财经APP获悉，瑞银发布研报称，汽车制造商附属保险公司的竞争威胁有限，相信凭借强大的定价 和理赔能力，中国财险(02328)将成为受益者，预计2025年比同行更快实现转机。因此，瑞银将中国财 险2025至2029年净利润预测分别上调3%至8%，目标价从20.7港元上调至21.8港元;重申"买入"评级。 瑞银预测2024年至2030年，内地新能源车保费年均复合增长率(CAGR)为27%，达到5,920亿人民币，主 要由车队规模推动。2024年新能源车行业综合成本率(CoR)为107%，预计2027年将实现转机。因此，瑞 银预测到2030年，新能源车承保利润将达到170亿人民币。 ...

国海证券指出，粉笔是公考培训赛道头部企业，产品、研发、技术能力优秀，看好AI产品渗透率提 升，带来增量收入空间。华泰证券则预计下半年随着国考临近，AI刷题班有望加速放量，预计全年销 量有望接近20万人次。考虑到新的AI产品具备更低的定价、更个性化和高效的学习体验、更难被盗版 等特征，在当下市场环境下具备较强竞争力和更稳健的盈利能力，该行认为中长期AI产品有望逐步替 代传统产品形态，并向更广泛的长尾用户渗透，推升用户增长和盈利天花板。 消息面上，今年4月，粉笔上线AI刷题系统班，定价399元，AI产品可以实时规划学习数据、动态定制 并调整学习计划，极大提升用户体验。截至2025年6月30日，已销售5万份，累计销售额约2000万元。此 外，8月底，粉笔AI矩阵再次迎来创新升级——事业单位AI刷题班正式上线，公司计划于年内在更多科 目推出AI大班课。值得一提的是，粉笔智能音箱上月正式上线并开启预售，24小时内，1400台预售库 存全部售罄。 粉笔(02469)涨超5%，截至发稿，涨5.15%，报3.06港元，成交额1.96亿港元。 ...

Core Viewpoint - The stock of Gilead Sciences-B (01672) rose over 4% following the announcement of promising clinical data for its long-acting GLP-1R agonist ASC30, indicating potential for quarterly dosing in weight management [1] Group 1: Clinical Developments - Gilead announced that its small molecule GLP-1R agonist ASC30 has shown a 75-day apparent half-life in obese subjects, suggesting a long-term weight management solution [1] - The ASC30 formulation is developed using Gilead's Ultra Long-Acting Drug Development Platform (ULAP) [1] Group 2: Shareholder Commitments - Gilead's controlling shareholder has made a voluntary lock-up commitment, agreeing not to sell any shares before the release of three key clinical data points [1] - The three data points include: 1. Topline data from the U.S. Phase I clinical study of ASC47 combined with semaglutide, expected by the end of September 2025 [1] 2. Topline data from the U.S. 13-week Phase IIa clinical study of ASC30 oral tablets in overweight or obese subjects, expected by December 2025 [1] 3. Topline data from the U.S. Phase I single ascending dose study of ASC50 in healthy subjects, expected by December 2025 [1]

（文章来源：每日经济新闻） 每经AI快讯，9月15日，港股煤炭股午后走高，MONGOL MINING涨超12%，兖矿能源涨超5%，中国 秦发涨超3%，易大宗、中国神华涨超2%。 ...

Group 1 - China Shengmu (01432) shares rose over 10%, reaching 0.33 HKD with a trading volume of 6.1415 million HKD [1] - China Shengmu Organic Dairy Co., Ltd. was awarded the title of "Benchmark Enterprise" for the "Animal-Friendly Farm Level Evaluation Standard," becoming one of the first companies in China to receive this certification [1] - The T/CVDA 38-2025 "Animal-Friendly Farm Level Evaluation - Dairy Cattle" standard was released, with China Shengmu being a key drafting unit, contributing significantly to its formulation [1] Group 2 - Tianfeng Securities indicated that raw milk prices are at a low point, awaiting a new cycle, with expectations for a prolonged upward cycle due to long recovery periods and low efficiency [1] - The current phase of cow capacity reduction is nearing its end, and the financial pressure from Q3 silage purchases may accelerate the clearing of marginal costs, leading to a potential rebound in raw milk prices [1] - Companies with cow resources or those adopting a "milk-meat linkage" model are expected to have more prominent profitability [1]

Group 1 - China Shengmu (01432) shares rose over 10%, currently up 10.00% at HKD 0.33, with a trading volume of HKD 6.1415 million [1] - China Shengmu Organic Dairy Co., Ltd. has been awarded the title of "Benchmark Enterprise" under the "Animal-Friendly Farm Level Evaluation Standard," becoming one of the first companies in China to receive "Animal-Friendly" farm certification [1] - The T/CVDA 38-2025 "Animal-Friendly Farm Level Evaluation - Dairy Cattle" standard was released, with China Shengmu being a key drafting unit, contributing significantly to the standard's formulation [1] Group 2 - Tianfeng Securities (601162) indicates that raw milk prices are stabilizing at low levels, awaiting a new cycle [1] - Due to long recovery periods and low efficiency, the current upward cycle is expected to last longer [1] - The current reduction in dairy cow capacity may be nearing its end, and the financial pressure from Q3 silage purchases could accelerate the clearing process, with raw milk prices likely to bottom out and rebound [1] - Companies with cow resources or those adopting a "milk-meat linkage" model are expected to have stronger profitability [1]

人民财讯9月15日电，零跑汽车官微发文称，近期，中国汽车工业协会发布了《汽车整车企业供应商账 款支付规范倡议》，得到了工信部等国家相关部门回应和支持。零跑汽车将继续贯彻落实《保障中小企 业款项支付条例》要求，并以切实行动响应《汽车整车企业供应商账款支付规范倡议》，持续保障产业 链供应链稳定，致力于构建良好的供应商生态。 （原标题：零跑汽车：将以切实行动响应《汽车整车企业供应商账款支付规范倡议》） ...